The concern of generic rivalry has consistently loomed around copyright’s iconic drug, Viagra, triggering questions about the outlook of similar pharmaceutical holdings. While first years saw impressive gains, the patent expiration has created the path for cheaper substitutes, potentially reducing earnings and presenting a genuine hazard for stak